Correspondence 0001493152-24-051813 from Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899) (PTIX)

Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)
Date: Dec. 23, 2024 · CIK: 0001022899 · Accession: 0001493152-24-051813

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-283949

Date

December 20, 2024

Author

Chief

Form

CORRESP

Company

Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)

Letter

Protagenic Therapeutics, Inc.

Fifth Avenue

New York, NY 10010

December 23, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

Re: Protagenic Therapeutics, Inc.

Registration Statement on Form S-1

Filed December 20, 2024

File No. 333-283949

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-1 (File No. 333-283949) filed with the U.S. Securities and Exchange Commission (the “Commission”) on December 20, 2024 (the “Registration Statement”), be declared effective on December 26, 2024, at 9:00 am, Eastern Standard Time, or as soon as practicable thereafter.

Very
truly yours,
PROTAGENIC
THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

Protagenic
Therapeutics, Inc.

149
Fifth Avenue

New
York, NY 10010

December
23, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    Re:
    Protagenic
                                            Therapeutics, Inc.

    Registration
    Statement on Form S-1

    Filed
    December 20, 2024

    File
    No. 333-283949

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned
hereby requests that the Company’s Registration Statement on Form S-1 (File No. 333-283949) filed with the U.S. Securities and
Exchange Commission (the “Commission”) on December 20, 2024 (the “Registration Statement”), be declared effective
on December 26, 2024, at 9:00 am, Eastern Standard Time, or as soon as practicable thereafter.

    Very
    truly yours,

    PROTAGENIC
    THERAPEUTICS, INC.

    By:
    /s/
    Alexander K. Arrow

    Alexander
                                            K. Arrow

    Chief
    Financial Officer

cc:
Dean Colucci, Duane Morris LLP

SecProbe.io